Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Baxter
Boehringer Ingelheim
Medtronic
Dow

Last Updated: January 25, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LUNESTA

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Lunesta

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00120250 ↗ Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder Completed Massachusetts General Hospital Phase 4 2005-06-01 The purpose of this study is to obtain data investigating the safety and efficacy of eszopiclone for the treatment of post-traumatic stress disorder (PTSD)-related sleep disturbance and the impact of improved sleep with eszopiclone treatment on neuroendocrine correlates of PTSD. The investigators hypothesize that eszopiclone will be significantly more effective than placebo and well tolerated for PTSD-related sleep disturbance, improvement in sleep will be associated with improvement in overall PTSD symptoms, and patients with PTSD-related sleep disturbances will have abnormal levels of stress hormones.
NCT00235508 ↗ Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder Completed Sunovion Phase 4 2005-06-01 To determine the safety and efficacy of eszopiclone as adjunctive therapy in the treatment of insomnia in patients with insomnia related to Generalized Anxiety Disorder. All subjects will receive an approved anxiolytic agent and will be randomized to nightly therapy with either eszopiclone or placebo.
NCT00283790 ↗ Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo Completed Sanofi Phase 4 2006-01-01 Investigation of Psychomotor and Cognitive Residual Effects of Single Oral Doses of Zolpidem Tartrate Extended Release 12.5 mg and Eszopiclone 3 mg Compared to Placebo in Healthy Young Volunteers, Using Flurazepam 30 mg as an External Comparator
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lunesta

Condition Name

Condition Name for Lunesta
Intervention Trials
Insomnia 17
Primary Insomnia 7
Obstructive Sleep Apnea 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lunesta
Intervention Trials
Sleep Initiation and Maintenance Disorders 27
Sleep Apnea, Obstructive 7
Sleep Apnea Syndromes 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lunesta

Trials by Country

Trials by Country for Lunesta
Location Trials
United States 158
United Kingdom 5
Ukraine 2
India 2
Croatia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lunesta
Location Trials
Massachusetts 15
California 10
Ohio 7
North Carolina 6
New York 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lunesta

Clinical Trial Phase

Clinical Trial Phase for Lunesta
Clinical Trial Phase Trials
Phase 4 20
Phase 3 6
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lunesta
Clinical Trial Phase Trials
Completed 36
Terminated 3
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lunesta

Sponsor Name

Sponsor Name for Lunesta
Sponsor Trials
Sunovion 27
Massachusetts General Hospital 5
University of California, San Diego 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lunesta
Sponsor Trials
Other 36
Industry 32
U.S. Fed 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Baxter
McKesson
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.